Aromaxyl 25 - Kalpa Pharmaceuticals

Exemestane was introduced as a third-generation aromatase inhibitor with a steroidal structure, making it a "suicide" inhibitor due to irreversible binding. Developed by Pharmacia and approved in 1999, it was released as Aromasin in 2000. The drug was intended for postmenopausal women whose breast cancer progressed after tamoxifen. Exemestane lowers estrogen by permanently deactivating aromatase. In sports contexts, it is used off-label to manage estrogenic effects of anabolic steroids, such as bloating and gynecomastia, without suppressing IGF-1 as strongly as other inhibitors.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Aromaxyl 25 by Kalpa Pharmaceuticals, consult with your doctor or healthcare professional.